Tirzepatide ZPHC — 50 mg (5 vials × 10 mg)

Tirzepatide – 5 vials × 10 mg (total 50 mg)
Dual GLP-1 / GIP agonist: advanced incretin peptide shown to deliver remarkable weight-loss and improved glycaemic control.
Once-weekly convenience: long half-life provides steady appetite suppression and blood-sugar regulation for 7 days.
Lyophilised 10 mg vials: reconstitute each vial with 1 ml bacteriostatic water to yield a 10 mg/ml solution (0.1 ml ≈ 1 mg).
Research dosing guide: initiate at 2.5 mg once weekly, escalate to 5 – 10 mg over 4–8 weeks; study durations 12–24 weeks.
Pharma-grade QC: ZPHC batches ≥ 99 % purity, endotoxin-free; tamper-evident box with scratch-code authenticity.
Cold-chain packed • discreet worldwide shipping • multilingual support.